PMC:7402624 / 3586-3688 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"89","span":{"begin":49,"end":58},"obj":"Species"},{"id":"93","span":{"begin":59,"end":68},"obj":"Disease"}],"attributes":[{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":49,"end":53},"obj":"Disease"},{"id":"T28","span":{"begin":59,"end":68},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T27","span":{"begin":0,"end":102},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}